Dr Choueiri Highlights Nivolumab Plus Cabozantinib vs Sunitinib for Advanced RCC

02/16/2021

Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, shares results from a new analysis of the phase 3 Checkmate 9ER trial of cabozantinib combined with nivolumab for the first-line treatment of advanced renal cell carcinoma (RCC). These data were presented at the 2021 Virtual ASCO Genitourinary Cancers Symposium.

Recent News

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...

Landmark 4-year analysis results...

10/04/2024

Oncology

News

Determining Optimal Daunorubicin Dosing and 7 + 3 Induction Cycles for Frontline AML Treatment

10/04/2024

Amber Denham ;

High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...

High-dose daunorubicin once...

10/04/2024

Oncology

News

Luspatercept Improves Anemia Among Patients With Myelofibrosis With or Without Transfusion Dependence

10/04/2024

Amber Denham ;

Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.

Luspatercept improved anemia and...

10/04/2024

Oncology

FDA Approval

FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer

10/03/2024

Stephanie Holland ;

Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...

Based on results from the...

10/03/2024

Oncology

News

Investigating Low-Dose Subcutaneous Decitabine Treatment for Patients With Myelofibrosis

10/02/2024

Amber Denham ;

According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...

According to a prospective phase...

10/02/2024

Oncology

News

Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer

10/02/2024

Allison Casey ;

The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.

The phase 3 SAKK 41/13 trial...

10/02/2024

Oncology

News

Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS

10/02/2024

Amber Denham ;

Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.

Luspatercept provides a new...

10/02/2024

Oncology

Conference Coverage

Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer

10/01/2024

Stephanie Holland ;

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

According to interim analysis...

10/01/2024

Oncology

FDA Approval

FDA Approves Selpercatinib for Adult and Pediatric Patients With Advanced or Metastatic Medullary Thyroid Cancer

09/27/2024

Stephanie Holland ;

Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.

Based on results from the phase...

09/27/2024

Oncology

News

Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma

09/26/2024

Amber Denham ;

According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.

According to results from a...

09/26/2024

Oncology